Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician?s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PDL1 Agents in the Early Setting Whose Tumors do Express PD-L1

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05382299

Study #:
STUDY00148722

Start Date:
Dec 07, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05382299

View Complete Trial Details & Eligibility at ClinicalTrials.gov